Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Mar;10(3):e150-e151.
doi: 10.1016/S2352-3018(23)00006-1. Epub 2023 Feb 8.

Need for clear inclusion criteria in reviews of antiretroviral treatments - Authors' reply

Kevin M Gibas  1 , Jose R Arribas  2 , Pedro Cahn  3 , Eric S Daar  4 , Babafemi O Taiwo  5
Affiliations
Comment

Need for clear inclusion criteria in reviews of antiretroviral treatments - Authors' reply

Kevin M Gibas et al. Lancet HIV. 2023 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

KMG received a training grant from the Agency For Health Care Research and Quality (T32HS026122). JRA has received advisory fees, speaker fees, and grant support from ViiV, Janssen, Gilead, Merck, Aelix, and Thera. PC has worked on advisory boards at ViiV and Merck, received research and speaker funds from ViiV, CanSino, and Janssen, and has received honoraria as a data safety and monitoring board member for Moderna. ESD has received research support from and is a consultant for Gilead, Merck, GlaxoSmithKline, and ViiV. BOT has served as a consultant and received honoraria from GlaxoSmithKline, ViiV, Gilead, Merck, and Johnson & Johnson.

Comment on

References

    1. Gibas KM, Kelly SG, Arribas JR, et al. Two-drug regimens for HIV treatment. Lancet HIV 2022; 9: e868–83. - PMC - PubMed
    1. Diaco ND, Strickler C, Giezendanner S, Wirz SA, Tarr PE. Systematic de-escalation of successful triple antiretroviral therapy to dual therapy with dolutegravir plus emtricitabine or lamivudine in Swiss HIV-positive persons. EClinicalMedicine 2018; 6: 21–25. - PMC - PubMed
    1. Sculier D, Wandeler G, Yerly S, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial. PLoS Med 2020; 17: e1003421. - PMC - PubMed
    1. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment guidance for industry. 2015. https://www.fda.gov/files/drugs/published/Human-Immunodeficiency-Virus-1... (accessed Dec 5, 2022).

MeSH terms